Navigation Links
Tragara Initiates Clinical Study of TG02 in Combination with Carfilzomib in Multiple Myeloma
Date:12/3/2013

San Diego (PRWEB) December 03, 2013

Tragara Pharmaceuticals, Inc. today announced the initiation of a phase 1b clinical trial of TG02, in combination with the poteosome inhibitor carfilzomib (Kyprolis®), in patients with relapsed or refractory multiple myeloma. TG02 is a potent oral inhibitor of CDK9, which leads to the depletion of key survival proteins, such as Mcl-1, resulting in p53-independent apoptosis across a wide range of tumor cells. The study is being led by Craig C. Hofmeister, M.D., at The Ohio State University Comprehensive Cancer Center, and is open for enrollment at multiple centers in the U.S.

This study is an open-label dose-escalation phase 1b trial in which TG02 is combined with carfilzomib in patients with relapsed or refractory multiple myeloma. The trial will include patients who have one or more cytogenetic abnormalities that predict poor prognosis and reduced responsiveness to current standard-of-care therapies, including deletion of chromosomes 17p or 1p, amplification of chromosome 1q, or the chromosomal translocation t(4:14). Patients who have received at least two prior therapies, including a proteasome inhibitor and an immunomodulatory agent, will also qualify for enrollment. The primary objective of the trial is to determine the dose-limiting toxicity, maximum-tolerated dose, and recommended phase II dose of TG02 in combination with carfilzomib. The secondary objectives include the assessment of safety, tolerability, pharmacokinetics, and the evaluation of exploratory biomarkers, in addition to evidence of anti-tumor activity.

“A meaningful percentage of patients with multiple myeloma have disease characterized by cytogenetic abnormalities, and the prognosis for these cases is typically poor,” said Craig C. Hofmeister, M.D., Assistant Professor at The Ohio State University, College of Medicine, and principal investigator. “The treatment options for this subset of patients ar
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. UK initiates first cancer reporting model of its kind in US
2. South Charlotte Dentistry Initiates New Emphasis on Comprehensive Dental Treatment
3. Taglich Brothers Initiates Coverage on FluroPharma Medical, Inc.
4. HCG Drops 411 Initiates 21 Pound Guarantee
5. Grant initiates new stem cell research for patients suffering with corneal blindness
6. Targeted Medical Pharma Initiates Clinical Trial of Red Blood Cell Stimulating Formulation
7. Scott Sheldon Initiates Change in Consulting Industry
8. First targeted nanomedicine to enter human clinical studies
9. Clinical insight improves treatment with new lung cancer drug
10. Clinical news alert from the American Academy of Orthopaedic Surgeons
11. NYU Langone experts present research, clinical advances at neurosurgeons meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2015)... May 30, 2015 Responding to surging ... travelers who experienced OGAWA products while abroad, OGAWA-engineered massage ... , A leader in the Asian health and ... designer, researcher, developer and manufacturer of health and wellness ... craftsmanship of their products, health enthusiasts in Asia and ...
(Date:5/30/2015)... Wixom, Michigan: Proof. Pest Control, a family-owned company ... new twist to its robust line of services-a 100% ... for general pest management. , “We like killing ... Branch Manager. “The average person cringes when they see a ... problems that most people don’t even want to think about. ...
(Date:5/30/2015)... “ Milli the Snail ” was featured on NewsWatch as ... the latest and coolest applications on the market for iOS, ... technology expert, conducted the app review and shared with viewers ... children. , Interactive mobile games for children have become quite ... they are playing are doing much for their intellectual development. ...
(Date:5/29/2015)... “In the current environment of ... regulations, we provide education that will help practitioners ... suffering from pain, within the boundaries of the ... of rehabilitation medicine and President/Medical Director of the ... , A new flight of PAINWeekEnd Regional Conferences ...
(Date:5/29/2015)... M3 USA MDLinx.com, source of the ... specialties, now offers The Smartest Rheumatologist . The ... disorders ranging from Fibromyalgia and Osteoporosis, to Arthritis and ... MDLinx, and Caroline Tredway, editorial head of The Smartest ... have on the physicians who participate. Says Tredway, “With ...
Breaking Medicine News(10 mins):Health News:Award-winning OGAWA Massage Chairs Finally Available for purchase in North America. 2Health News:Award-winning OGAWA Massage Chairs Finally Available for purchase in North America. 3Health News:Proof. Pest Control-Now Offering 100% Organic Pest Control in Southeast Michigan 2Health News:An Aesthetic Game that Engages and Educates Children was Featured on NewsWatch Television 2Health News:PAINWeekEnd Kansas City: Pain Management CME for the Main Street Practitioner 2Health News:MDLinx Launches Smartest Rheumatologist 2
... Blue Plans in Oregon and Washington ... from HealthLeaders-InterStudy, NASHVILLE, Tenn., July 29 ... reports that Regence,BlueCross BlueShield of Oregon and Regence ... significant play in the Medicare market.,According to the ...
... For International Licensing, LAS VEGAS, July ... http://www.skinvisible.com, , http://www.invisicare.com ), the developers of ... topical skincare products, announces,the successful development of ... ingredient avobenzone (Parsol(R) 1789) with Invisicare. Avobenzone,is ...
... July 29 Studies show that regular,monitoring of ... improve a,patient,s quality of health. Thanks to recent ... all sorts of information about their,patients that they ... with reports that show how regularly,their chronically ill ...
... team of scientists has identified processes that are heavily implicated ... us closer to developing quick tests and readouts that could ... the white blood cells that produce antibodies, form a key ... to maintain the right number of B cells, not too ...
... could quadruple in certain populations if people with HIV ... the Swiss Federal Commission for HIV/AIDS, University of New ... from UNSW,s National Centre in HIV Epidemiology and Clinical ... experts from the Swiss Federal Commission for HIV/AIDS that ...
... spouse quits , , TUESDAY, July 29 (HealthDay News) -- Nonsmokers ... for experiencing a stroke, a new study suggests. , Researchers ... still smoke carry an even greater risk for stroke. However, ... any higher risk for stroke than those married to someone ...
Cached Medicine News:Health News:Regence Group's Oregon and Washington Blue Plans Are Well Positioned for Success in Local Medicare Market 2Health News:Skinvisible Offers 8 Hour Photostablity for Parsol 1789 2Health News:Skinvisible Offers 8 Hour Photostablity for Parsol 1789 3Health News:Highmark's SMART(TM) Registry Reports Aid the Chronically Ill 2Health News:Highmark's SMART(TM) Registry Reports Aid the Chronically Ill 3Health News:How molecules out of balance lead to human multiple myeloma and other cancers 2Health News:A dangerous precedent in HIV 2Health News:Secondhand Smoke Raises Stroke Risk for Spouses 2Health News:Secondhand Smoke Raises Stroke Risk for Spouses 3
(Date:5/29/2015)... SACRAMENTO, Calif. , May 29, 2015  Anpac ... Dr. Chris Yu and the Anpac research ... Summit on Biomedical Science (NPLS) organizers published as, "game ... at the American Society of Clinical Oncology (ASCO) Annual ... 29 – June 2, 2015. An ...
(Date:5/29/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/p37spr/north_america ) has announced ... MRI Market - Growth, Trends And Forecasts (2014 - ... key players in the industry are GE , Hitachi ... Medical Systems MRI is a ... its higher sensitivity and use of non-ionizing radiations. Open ...
(Date:5/29/2015)... Massachusetts and SPARTANBURG, South Carolina ... The Guardian Research Network and Molecular Health have announced ... and molecular diagnostic decision support to the majority of ... Guardian Research Network will collaborate with Molecular Health to ... testing to identify cohorts from hundreds of thousands of ...
Breaking Medicine Technology:Anpac Bio-Medical Introduces 'Game Changing' Cancer Screening Tech at American Society of Clinical Oncology Meeting - Chicago 5/29 - 6/2 2Anpac Bio-Medical Introduces 'Game Changing' Cancer Screening Tech at American Society of Clinical Oncology Meeting - Chicago 5/29 - 6/2 3North America Open System MRI Market 2014-2019 with GE, Hitachi Medical, Philips Healthcare, Siemens Healthcare and Toshiba Medical Dominating 2New Collaboration to Dramatically Expand Therapeutic Clinical Trial Access for Cancer Patients Across the United States 2New Collaboration to Dramatically Expand Therapeutic Clinical Trial Access for Cancer Patients Across the United States 3New Collaboration to Dramatically Expand Therapeutic Clinical Trial Access for Cancer Patients Across the United States 4
... POTTERS BAR, England, Oct. 25, 2011 Mylan Inc. (Nasdaq: ... has launched Rivastigmine Capsules POM, 1.5 mg, 3 mg, 4.5 ... of Novartis, Exelon ® Capsules, a treatment for dementia ... to launch a generic Rivastigmine formulation in the U.K. ...
... 2011 Reportlinker.com announces that a ... in its catalogue: ... Market to 2017 - Multiple Sclerosis, ... for Half the Market Value in ...
Cached Medicine Technology:Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 2Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 3Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 4Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 5Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 6Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 7Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 8Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 9Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 10Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 11Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 12Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 13Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 14Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 15Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 16Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 17Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 18Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 19Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 20
Colloidal Gold Conjugated, Rabbit anti-goat IgG (H&L) - 50 OD...
Colloidal Gold Conjugated, Goat anti-rabbit IgG (H&L) - 50 OD...
Colloidal Gold Conjugated, Goat anti-human IgG (H&L) - 12 OD...
Colloidal Gold Conjugated, Goat anti-human IgA (Alpha Chain) - 12 OD...
Medicine Products: